Pradaxa Achieves Blockbuster Status

This is Michael Brady Lynch, Lead Trial Attorney for The Michael Brady Lynch Firm.

It was with great fanfare that Pradaxa manufacturer Boehringer Ingelheim Pradaxa Acbhieves Blockbuster StatusPharmaceuticals announced last week that Pradaxa had achieved the status of a “blockbuster drug” (blockbuster status is defined as generating annual sales of $1 billion or more). Ironically, this announcement comes on the eve of FDA data confirming that Pradaxa users reported more than 3,000 cases of side effects from Pradaxa bleeding in just the last three months of 2011. The 3,000 reports of Pradaxa side effects included 459 deaths, 69 disabilities, and 1,331 hospitalizations all due to Pradaxa bleeding.

Pradaxa Lawsuits

Hot on the heels of the “blockbuster” announcement, more Pradaxa bleeding lawsuits continue to be filed every day. These claims have been filed against Pradaxa manufacturer Boehringer Ingelheim Pharmaceuticals, fueled by the reports of 3,000 reports of Pradaxa side effects included 459 deaths, 69 disabilities, and 1,331 hospitalizations all due to Pradaxa bleeding dangers.

If you have been a victim of a Pradaxa-related injury or if you or someone you love was taking Pradaxa and suffered a bleeding event, I urge you to contact me directly for a free, no-obligation evaluation of your Pradaxa case.

About the Firm: The Michael Brady Lynch Firm is a trial firm with a focus on pharmaceutical mass tort cases involving SSRI and Anti-Seizure Medication Birth Defects such as Lexapro, Zoloft, Effexor, Prozac, Celexa, Paxil, Depakote and Topamax, as well as Actos Bladder Cancer and Fosamax Femur Fractures, and medical device cases including DePuy Hip and Trans-Vaginal Mesh cases. Contact us today if you or someone you know has experienced side effects involving these products.

Leave a Reply

Your email address will not be published. Required fields are marked *

Contact Us Today

Contact our lawyers directly through the email form below.
  • * Denotes a required field
  • This field is for validation purposes and should be left unchanged.